Celgene
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Celgene sits in the top decile of US sponsors by registered trial count (#115 of 15,742 sponsors by registered trial count).
Celgene: 308 sponsored US clinical trials, 12 recruiting.
Celgene sponsors 308 registered US clinical trials on ClinicalTrials.gov, 12 of them currently recruiting, and 221 completed. 57 of these trials are in Phase 3-4 (later-stage) and 236 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Myeloma, with 11 trials.
Top-decile sponsor footprint
Celgene ranks in the top decile of sponsors by registered trial count (#115 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
221 of 282 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
308 total, page 6 of 7
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT00963105
Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)
NCT00910910
Connect® MM- The Multiple Myeloma Disease Registry
NCT01081028
Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma
NCT00975806
A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.
NCT00915083
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
NCT00864253
Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
NCT00844649
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy
NCT00774345
A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial
NCT00737529
Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer
NCT00688415
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
NCT00652626
Trial of Romidepsin and Bortezomib for Multiple Myeloma
NCT00765102
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
NCT00689936
Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma
NCT00761722
Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma
NCT00717522
A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma
NCT00655668
A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide
NCT00537511
ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies
NCT00635284
Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer
NCT00540514
ABI-008 Trial in Patients With Metastatic Breast Cancer
NCT00531271
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
NCT00528983
AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy
NCT00547651
Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease
NCT01522547
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
NCT00426764
A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes
NCT00458159
A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia
NCT00463385
ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer
NCT00477529
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
NCT00461045
A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia
NCT00419250
Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy
NCT00375193
Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer
NCT00398086
ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma
NCT00407407
AVIDA The Vidaza® (Azacitidine) Patient Registry
NCT00481273
Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
NCT00394251
A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors
NCT00379639
ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer
NCT00394082
A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma
NCT00413036
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma
NCT00396864
Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
NCT00281528
Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis
NCT00249002
Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy
NCT00179608
A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer
NCT00140140
Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
NCT00179673
Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes
NCT00102687
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
NCT00106431
Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer
NCT00093145
Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228
NCT00106301
A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care
NCT00071799
Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma
NCT00065351
Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma
NCT00093119
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 161 |
| Phase 2 | 75 |
| Phase 3 | 56 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Celgene pipeline
12 recruiting of 308 indexed (4% open); 221 completed (72%).
Phase mix: 57 late (III/IV) vs 236 early (I/II) (early-phase heavy).
Top condition: Multiple Myeloma (11 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Celgene: open-pipeline peers nationwide
Peers matched on 308 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Celgene sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 308 trials (± recruiting share)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 305 trials · 8% recruiting
- Allergan · 314 trials · 0% recruiting
- University of Arkansas · 318 trials · 12% recruiting
- Rush University Medical Center · 320 trials · 17% recruiting
Sponsors near 4% open enrollment (± trial volume)
- U.S. Army Medical Research and Development Command · 4% recruiting · 77 trials
- MedtronicNeuro · 4% recruiting · 51 trials
- Aldeyra Therapeutics · 4% recruiting · 26 trials
- DexCom · 4% recruiting · 26 trials
Related
What to do with this Celgene page
308 registered trials is a research-attention snapshot, not an endorsement of Celgene or any single study.
- 12 of Celgene's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Multiple Myeloma is the condition Celgene studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Myeloma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Celgene pipeline card: 308 registered trials from official public datasets.Report a data error.